Desirée van Noord

Desirée van Noord

Auto-generated profile, based on publicly available information

Desirée van Noord

Department of Gastroenterology & Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
DNDesirée van Noord
Desirée van Noord
JKJeroen J. Kolkman
Jeroen J. Kolkman

20 August 2019 in Trials
Verified
Journal Article
Open access
PDF file
O(on behalf of the Dutch Mesenteric Ischemia Study group (DMIS)
on behalf of the Dutch Mesenteric Ischemia Study group (DMIS)
LDLouisa J. D. van Dijk
Louisa J. D. van Dijk
JHJihan Harki
Jihan Harki
DNDesirée van Noord
Desirée van Noord
HVH.J.M. Verhagen
H.J.M. Verhagen
AMAdriaan Moelker
Adriaan Moelker
Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to the gastrointestinal tract and is caused by atherosclerotic stenosis of one or more mesenteric arteries in > 90% of cases. Revascularization therapy is indicated in patients with a diagnosis of atherosclerotic CMI to relieve symptoms and to prevent acute-on-chronic mesenteric ischemia, which is associated with high morbidity and mortality. Endovascular therapy has rapidly evolved and has replaced surgery as the first choice of treatment in CMI. Bare-metal stents (BMS) are standard care currently, although retrospective studies suggested significantly higher patency rates for covered stents (CS). The Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI) trial is designed to prospectively assess the patency of CS versus BMS in patients with atherosclerotic CMI. The CoBaGI trial is a randomized controlled, parallel-group, patient- and investigator-blinded, superiority, multicenter trial conducted in six centers of the Dutch Mesenteric Ischemia Study group (DMIS). Eighty-four patients with a consensus diagnosis of atherosclerotic CMI are 1:1 randomized to either a balloon-expandable BMS (Palmaz Blue with rapid-exchange delivery system, Cordis Corporation, Bridgewater, NJ, USA) or a balloon-expandable CS (Advanta V12 over-the-wire, Atrium Maquet Getinge Group, Hudson, NH, USA). The primary endpoint is the primary stent-patency rate at 24 months assessed with CT angiography. Secondary endpoints are primary stent patency at 6 and 12 months and secondary patency rates, freedom from restenosis, freedom from symptom recurrence, freedom from re-intervention, quality of life according the EQ-5D-5 L and SF-36 and cost-effectiveness at 6, 12 and 24 months. The CoBaGI trial is designed to assess the patency rates of CS versus BMS in patients treated for CMI caused by atherosclerotic mesenteric stenosis. Furthermore, the CoBaGI trial should provide insights in the quality of life of these patients before and after stenting and its cost-effectiveness. The CoBaGI trial is the first randomized controlled trial performed in CMI caused by atherosclerotic mesenteric artery stenosis. ClinicalTrials.gov, ID: NCT02428582 . Registered on 29 April 2015.

1 November 2019 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
LDLouisa Jd van Dijk
Louisa Jd van Dijk
DNDesirée van Noord
Desirée van Noord
RGRobert H Geelkerken
Robert H Geelkerken
JHJihan Harki
Jihan Harki
SBSophie A Berendsen
Sophie A Berendsen
DGDutch Mesenteric Ischemia Study group
Dutch Mesenteric Ischemia Study group
Background and objective: The objective of this article is to externally validate and update a recently published score chart for chronic mesenteric ischemia (CMI).Methods: A multicenter prospective cohort analysis was conducted of 666 CMI‐suspected patients referred to two Dutch specialized CMI centers. Multidisciplinary consultation resulted in expert‐based consensus diagnosis after which CMI consensus patients were treated. A definitive diagnosis of CMI was established if successful treatment resulted in durable symptom relief. The absolute CMI risk was calculated and discriminative ability of the original chart was assessed by the c‐statistic in the validation cohort. Thereafter the original score chart was updated based on the performance in the combined original and validation cohort with inclusion of celiac artery (CA) stenosis cause.Results: In 8% of low‐risk patients, 39% of intermediate‐risk patients and 94% of high‐risk patients of the validation cohort, CMI was diagnosed. Discriminative ability of the original model was acceptable (c‐statistic 0.79). The total score of the updated chart ranged from 0 to 28 points (low risk 19% absolute CMI risk, intermediate risk 45%, and high risk 92%). The discriminative ability of the updated chart was slightly better (c‐statistic 0.80).Conclusion: The CMI prediction model performs and discriminates well in the validation cohort. The updated score chart has excellent discriminative ability and is useful in clinical decision making.

1 January 2019 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
LDLouisa J.D. van Dijk
Louisa J.D. van Dijk
JHJihan Harki
Jihan Harki
DNDesirée van Noord
Desirée van Noord
AVAnnemarie C. de Vries
Annemarie C. de Vries
AMAdriaan Moelker
Adriaan Moelker
Marco BrunoMarco Bruno
Marco Bruno

20 October 2023 in Journal of Open Research Software
Verified
Journal Article
Closed access
RLReinier Cornelis Anthonius van Linschoten
Reinier Cornelis Anthonius van Linschoten
SKSebastiaan Laurens Knijnenburg
Sebastiaan Laurens Knijnenburg
RWRachel Louise West
Rachel Louise West
DNDesirée van Noord
Desirée van Noord

4 February 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
RLReinier C A van Linschoten
Reinier C A van Linschoten
NLNikki van Leeuwen
Nikki van Leeuwen
DKDavid van Klaveren
David van Klaveren
MPMarieke J. Pierik
Marieke J. Pierik
RCRob Creemers
Rob Creemers
DNDesirée van Noord
Desirée van Noord
Background and aims: Large registries are promising tools to study the epidemiology of inflammatory bowel disease (IBD). We aimed to develop and validate machine learning models to identify IBD cases in administrative data, aiming to determine the prevalence, incidence, and mortality of IBD in the Netherlands. Methods: We developed machine learning models for administrative data to identify IBD cases and classify them on subtype and incidence year. Models were developed in a population-based cohort and externally validated in a hospital cohort. Models were evaluated on Brier score, area under the receiver operating characteristic curve (AUC), calibration, and accuracy. The best models were used to determine the epidemiology of IBD in the Netherlands between 2013 and 2020. Results: For identifying IBD cases the random forest model was best (AUC: 0.97, 95% CI [0.96; 0.97]). The gradient-boosted trees model for subtype was best (accuracy: 0.95, 95% CI [0.94; 0.95]) as was the random forest model for incidence year (0.88, 95% CI [0.86; 0.89]). The prevalence of IBD in the Netherlands was 577.6 (95% CI [566.7; 586.2]) per 100 000 on December 31, 2020, with varying prevalence across the Netherlands. Incidence of IBD was 20.1 (95% CI [18.0; 22.3]) per 100 000 in 2020 and stable over time. Mortality rates of IBD patients rose over time and were 11.6 (95% CI [10.5; 11.8]) per 1000 in 2020 as compared to 9.5 in the general population. Conclusion: Inflammatory bowel disease cases can be accurately identified using administrative data. The prevalence of IBD in the Netherlands is increasing slower than expected, suggesting a trend towards the epidemiological stage of Prevalence Equilibrium.